Medicine
Pharmacogenomics of Warfarin Dosing: CYP2C9 and VKORC1
Quick fact
Two genetic variants in the CYP2C9 and VKORC1 genes can explain about 30-40% of the variability in warfarin dose requirements among patients, and genetic testing can help reduce the risk of hospitalization due to bleeding.
Why this is interesting
You and your neighbour take the same medication, but you need triple the dose to get the same effect. Why? For warfarin, the answer may be written in your genes.
Read the full explanation
Understanding Pharmacogenomics of Warfarin Dosing: CYP2C9 and VKORC1
Warfarin is a blood thinner commonly used to prevent blood clots. It works by blocking an enzyme called VKORC1, which is needed to recycle vitamin K, essential for making clotting factors. The challenge is that the effective dose varies greatly from person to person—too much causes bleeding, too little allows clots. Two genes are key: CYP2C9 encodes an enzyme that breaks down warfarin, and VKORC1 encodes the very enzyme warfarin targets. Variations (polymorphisms) in these genes can make the breakdown slower or the target more sensitive, meaning a lower dose is needed. Thus, by testing for these genetic variants, doctors can estimate a starting dose that is safer and more effective.
A deeper explanation
The pharmacogenomic mechanism involves two distinct levels. CYP2C9 is a phase I drug-metabolizing enzyme in the liver that inactivates the more potent S-enantiomer of warfarin. Common reduced-function alleles, CYP2C92 and CYP2C93, result in less enzyme activity, leading to higher plasma warfarin levels and increased bleeding risk if standard doses are used. VKORC1 encodes the target enzyme, vitamin K epoxide reductase complex subunit 1. Variants in the VKORC1 promoter, such as the -1639GA polymorphism, reduce transcription of the enzyme, making the drug more effective at lower doses. Therefore, carrying reduced-function CYP2C9 or sensitive VKORC1 genotypes requires lower maintenance doses. Clinical algorithms incorporate these genotypes along with age, weight, and other factors to predict a patient's therapeutic dose. This is a prime example of pharmacogenomics directly informing clinical decisions, moving from a one-size-fits-all approach to individualized therapy.